The majority of clinical studies establish TLR3 as a tumor suppressor using synthetic ligand polyinosinic:polycytidylic acid [poly(I:C)] or poly-ICLC for adjuvant therapy or targeted therapy (16–19). Here, TLR3 is linked to neoplasm.